Juliana Pereira

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine · 2015 · 375 citations · Full text

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen et al. · Journal of Clinical Oncology · 2019 · 143 citations · Full text

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Study of lymphocyte subpopulations in bone marrow in a model of protein–energy malnutrition

Ricardo Ambrósio Fock, Solange Lúcia Blatt, Beatriz Beutler et al. · Nutrition · 2009 · 97 citations · Full text

Sequence Variability of Human Erythroviruses Present in Bone Marrow of Brazilian Patients with Various Parvovirus B19-Related Hematological Symptoms

Sabri Saeed Sanabani, Walter Kleine Neto, Juliana Pereira et al. · Journal of Clinical Microbiology · 2006 · 97 citations · Full text